

## This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug delivery</b>			
Antibody-functionalized lipid-polymer nanoparticles for targeted drug delivery	<p>Targeted antibody-functionalized lipid-polymer nanoparticles could help deliver cancer therapeutics. Lipid-polymer nanoparticles linked to an antibody fragment targeting carcinoembryonic antigen (CEA) were loaded with paclitaxel. In CEA<sup>+</sup> human pancreatic cancer cells, the targeted paclitaxel-loaded nanoparticles showed greater cytotoxicity than untargeted paclitaxel-loaded nanoparticles (<math>p &lt; 0.01</math>). Next steps could include evaluating different combinations of cancer drugs and targeting molecules in preclinical models. At least nine companies have CEA-targeting compounds in Phase II or earlier to treat cancer.</p> <p><b>SciBX 3(18); doi:10.1038/scibx.2010.573</b>  <b>Published online May 6, 2010</b></p>	Patent and licensing status unavailable	<p>Hu, C.-M.J. <i>et al. Mol. Pharm.</i>; published online April 15, 2010; doi:10.1021/mp900316a</p> <p><b>Contact:</b> Michael Bouvet, University of California, San Diego Medical Center Moores Cancer Center, La Jolla, Calif.  e-mail: <a href="mailto:mbouvet@ucsd.edu">mbouvet@ucsd.edu</a></p> <p><b>Contact:</b> Liangfang Zhang, same affiliation as above  e-mail: <a href="mailto:zhang@ucsd.edu">zhang@ucsd.edu</a></p>